UCB (OTCMKTS:UCBJF) Stock Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• UCB SA's stock has crossed above its 50-day moving average of $231.36, trading at a high of $238.49 during recent sessions.
• Analysts from Morgan Stanley have restated an "overweight" rating on UCB shares, contributing to an overall average rating of "Buy" from market data.
• The company specializes in biopharmaceuticals for neurology and immunology diseases, with key products including Cimzia for inflammatory diseases and medications for epilepsy and Parkinson's disease.

UCB SA (OTCMKTS:UCBJF - Get Free Report) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $231.36 and traded as high as $238.49. UCB shares last traded at $238.49, with a volume of 25 shares changing hands.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an "overweight" rating on shares of UCB in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy".

UCB Trading Down 0.7%

The firm's fifty day moving average is $231.36 and its two-hundred day moving average is $196.56. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.